Cancer Treatment Centers of America
Cancer Treatment Centers of America
News Article | April 17, 2017
In 2007, not long after fulfilling her dream of living in Paris, France, Karla Baptiste was diagnosed with stage III breast cancer at the age of 34. She had just received her MBA and, like most new graduates, she was on top of the world and thinking ‘The best is yet to come!’ “I could not have been more optimistic. I never would have thought I would be battling breast cancer the following year!” she said. The cancer diagnosis was a shocker to say the least but she took solace in knowing that if her life were to end soon she had no regrets. She had followed her dream and lived it up in Paris like it was her last chance. Another dream of Baptiste’s was to become an author. When she was first diagnosed with breast cancer, she began reading breast cancer memoirs which only took the reader through treatment. Baptiste was always left wondering ‘what happened next?’. This inspired Baptiste to publish her own story. She started writing her memoir, Dig in Your Heels: The Glamorous (and Not So) Glamorous Life of a Young Breast Cancer Survivor, a couple of years after being diagnosed. She was hoping to tell her story from diagnosis to reaching the coveted five-year cancer-free anniversary. Fortunately, she is part of the 72% of women who survive beyond five years after a stage III breast cancer diagnosis. However, in July 2014, as Baptiste was preparing to publish her memoir, she discovered that her cancer had returned to her spine making it stage IV. Determined more than ever to share her message of hope, Baptiste turned to crowdfunding to raise money to publish her memoir. Her goal was $10,000 but she raised over $13,000 in two months! During the months of February and March, Baptiste will use her book and her crowdfunding chops to help raise money to establish an oncology center in her father’s birthplace, St. Vincent and the Grenadines— an island country in the Lesser Antilles in the Caribbean. Baptiste had always intended to use her memoir to give back. Typically, ten percent of the proceeds from the sale of Dig in Your Heels goes to breast cancer research and outreach. However, upon learning that cancer patients in her fatherland often forgo treatment and die because there isn’t a treatment center on the island, she wanted to give in a bigger way. The closest place to receive treatment for Vincentians is Trinidad making the cost and inconvenience of travel a hindrance to receiving care. In February, the St. Vincent and the Grenadines Medical Association launched an Indiegogo campaign to raise money for the new oncology center. Their goal is $250,000. “When I heard about the goal, I wished that I had sold more books so that I could fund the entire center myself. But after I thought about it, I realized that I could give 100% of my net proceeds now. Maybe my commitment to be “all in” would inspire others to give big too.” said Baptiste. “I know what it’s like to go through a cancer battle and it’s important to receive care close to your loved ones and not have to worry about added expenses. Having cancer is burden enough.” Dig in Your Heels: The Glamorous (and Not So) Glamorous Life of a Young Breast Cancer Survivor can be purchased at Amazon.com, Barnes & Noble, and iTunes. One hundred percent of the proceeds will go to establish the oncology center in St. Vincent. For more information about the book and the oncology center, visit www.diginyourheels.com. Karla Antoinette Baptiste was born and raised in Seattle, Washington. She has a Bachelor degree in Business Administration from the University of Washington and a Master of International Business from Schiller International University - Paris, France. When Baptiste was first diagnosed with breast cancer she was living in the San Francisco Bay Area and was treated at Diablo Valley Oncology. Upon moving to the Dallas, TX area in December of 2013, Baptiste was diagnosed with stage IV breast cancer and sought treatment at the Cancer Treatment Centers of America in Zion, IL. Baptiste is an ambassador for the Stanford Cancer Institute Community Partnership Program, which aims to reduce breast cancer disparities among African-American women. She is also a Cancer Fighters® ambassador for the Cancer Treatment Centers of America and a member of Sisters Network, Inc. Baptiste works in sales for a major Food and Beverage manufacturer and lives near Dallas, TX with her dog, Armani.
News Article | May 17, 2017
CRANBURY, N.J.--(BUSINESS WIRE)--CURE®, the nation's leading consumer digital and print media enterprise focused entirely on patients with cancer, has been honored by Healthline. CUREtoday.com offers viewers access to editorial content on clinical updates, video editorial series, and personal stories from individuals living with cancer as a part of its Voice’s section. This content, helped CUREtoday.com be honored as one of the best cancer blogs of 2017 by Healthline. CURE® was also recognized with The University of Texas MD Anderson Cancer Center, Cancer Treatment Centers of America and Stand Up To Cancer. “This honor is dedicated to those who contribute to the Voices section of CURE®. Our mission at CURE® is to provide research and beneficial information for patients, caregivers and survivors impacted by cancer,” said Michael J. Hennessy Jr., president of Michael J. Hennessy Associates, Inc., the parent company of CURE® magazine. Committed to providing expert content along with unconditional support, Healthline is one of the fastest growing health information sites. The award Best Cancer Blogs of the year is granted to blogs providing updated information, support, and strategies for living beyond the disease. CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc., family of businesses, which includes the acclaimed OncLive® (http://www.onclive.com) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com or http://www.mjhassoc.com.
News Article | May 15, 2017
CHANDLER, Ariz.--(BUSINESS WIRE)--On May 12, 2017, Governor Doug Ducey signed Arizona’s $9.8 billion 2018-2019 Budget which provides bonding authority for $1 billion for investments in University Research Infrastructure. This investment continues a collaboration between the State of Arizona, Industry Leaders, Philanthropists, and Arizona’s Universities that is driving Arizona towards its goal of becoming a top-tier bioscience state. The Biotechnology Innovation Organization in partnership with TEConomy Partners publishes the biennial report on the economic impact of the bioscience industry that provides a national overview and ranks the 50 states and Puerto Rico across five quintiles or tiers. The 2016 Report, The Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life 2016, was released in June of 2016 at the BIO International Convention in San Francisco. The report includes a wide range of metrics and economic indicators on a national and state basis. As reported in 2016, the top 10 states based on the number of bioscience firms (Tier I) were California, Florida, Illinois, Massachusetts, New Jersey, New York, North Carolina, Pennsylvania, Ohio, and Texas. Could Arizona achieve the growth necessary to reach the top-tiers? Arizona’s leaders began the journey to achieve this goal twenty years ago. In 1997, the Arizona Bioindustry Cluster was founded by Bob Case and Michael E. Berens, Ph.D. laying the foundation for what would become the Arizona Bioindustry Association or AZBio in 2003. Work by the Arizona Legislature and a coalition of community leaders supported voter passage of Proposition 301 in the year 2000. Prop. 301 established a six-tenths of one cent sales tax to support education that included funding for an estimated $1 billion (generated and disbursed over 20 years) for research at Arizona universities. The resulting Technology Research Initiative Fund (TRIF) is administered by the Arizona Board of Regents and has distributed $892 million for the period spanning from 2001-2016 and is well on its way to reach the billion dollar goal by June 30, 2021. The following year, the Flinn Foundation committed to 10 years of major funding for Arizona biosciences and brought together over 100 leaders to begin to craft what would become the Arizona Bioscience Roadmap. Under the stewardship of the Flinn Foundation, the strategic plan for the biosciences in Arizona would include key initiatives along with a commitment to measurement and reporting of the results. The first decade of the new century marked the completion of The Human Genome Project and a new era for life science research and development globally. From 2000 to 2010, Arizona’s Bioscience community activity included the International Genomics Consortium establishing its home in Phoenix and the subsequent creation of the Translational Genomics Research Institute (TGen) which was funded by a $90 million fundraising effort and spun out of IGC. In addition to the funding from Prop. 301, the Arizona legislature approved $440 million for construction of new university research facilities supporting the growth of the Biodesign Institute at Arizona State University, the BIO5 Institute at the University of Arizona, new research facilities at Northern Arizona University and more. An additional $100 million was approved by the voters for bioscience and health care training and facilities at Maricopa Community Colleges. The Virginia G. Piper Charitable Trust committed $50 million to personalized medicine in Arizona and local philanthropists have supported the community with additional resources for research and patient care across the state. Over the last two decades, Arizona’s bioscience industry has focused and grown. Arizona has risen in the rankings to take its place in the second tier of the Bioscience rankings based on number of firms. The Biodesign Institute at Arizona State University has grown from one building to two with a third building under construction. Arizona is now home to the Critical Path Institute, the National Biomarker Development Alliance, the Arizona Alzheimer’s Alliance, the Banner Alzheimer’s Institute, Cancer Treatment Centers of America, and Banner MD Anderson. Barrow Neurological Institute, founded in 1962 as a regional specialty center, has grown into one of the premiere destinations in the world for neurology and neurosurgery. Phoenix Children’s Hospital is now one of the largest children’s hospitals in the country and is ranked in 10 out of 10 specialties. Mayo Clinic has expanded its research and patient care capacity, added proton beam capabilities and will welcome the first class to its Arizona-based Mayo Medical School in 2017. The University of Arizona extended its reach from Tucson to Phoenix which now includes the The University of Arizona College of Medicine-Phoenix and the The University of Arizona Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center on the Phoenix Biomedical Campus. The number of life science companies in Arizona is now over 1,400 and multi-billion dollar exits include the sale of Ventana Medical Systems, Inc. to Roche for $3.4 Billion and Abraxis Biosciences for $2.9 billion to Celgene. Today, companies that were born in Arizona are now publicly traded including Insys, HTG Molecular, and SensTech while others have been acquired by AMAG Pharmaceuticals, Caris Diagnostics, Thermo Fischer, IMS Health, Merz, Stryker and more. These companies have continued to grow in Arizona joining global leaders including BARD, Medtronic, and W.L. Gore. The combined benefits of Arizona’s world-class healthcare institutions and diverse population demographics are driving the number of active clinical trials in the state which have more than doubled over the period from 2012 – 2017 based on data at ClinicalTrials.gov. Long-time residents and new industry partners are benefiting from Arizona’s business-friendly public policy and regulatory environment, affordable operating cost structures, stable and reliable energy suppliers, well-managed water resources, talent, and an affordable cost of living in communities that provide their employees the opportunity for an excellent quality of life. Free from the business disruptions that can be caused by earthquakes, hurricanes, tornadoes, and floods, Arizona has become a go-to site for both high-tech manufacturing and corporate data centers. The Arizona Innovation Challenge, which made its first awards in 2011 and is powered by the Arizona Commerce Authority, awards the most money in the country for a technology commercialization challenge – $3 million ($1.5 million twice yearly) to the world’s most promising technology ventures. Awards range from $100,000 to $250,000 per company. Over this 20-year span, Arizona has gained a reputation as the state with the “collaborative gene” and attracts thought leaders looking to discover, develop, and deliver life-changing and life-saving innovations to patients. Globally recognized thought leaders have left the hallowed halls of Harvard, the National Institutes of Health and other world-class institutions to innovate and collaborate in Arizona. One real-world example of this collaboration is Arizona State University’s International School of Biomedical Diagnostics. A global center for research, teaching and service in the emerging field of biomedical diagnostics, the school pulls expertise from faculty across ASU, in collaboration with Dublin City University (DCU), Ventana Medical Systems, and other industry partners. ASU faculty come from: the Biodesign Institute, College of Health Solutions, Ira A. Fulton Schools of Engineering, School of Life Sciences in the College of Liberal Arts and Sciences, the W. P. Carey School of Business, and the Consortium for Science, Policy & Outcomes. The initiative also leverages the expertise of the National Biomarker Development Alliance that is led by ASU. Under the leadership of President Michael Crow, Arizona State University has been named the Most Innovative University in the United states for two years running and out-ranking Stanford and MIT. Throughout the Arizona Bioscience Roadmap’s first decade, Battelle tracked performance data that was released annually by the Flinn Foundation. The performance metrics released in 2014 serve as the benchmark for the second decade of the Roadmap, with new data reported on a biennial basis. The most current data is available in “2015 Progress of the Biosciences in Arizona,” a report produced by TEConomy Partners (a spinoff of Battelle) that was released in March 2016. The Flinn Foundation will continue to track the progress of the bioscience sector each year by highlighting the state’s major developments. In April of 2017, the Flinn Foundation released its most recent update, the 2016 Progress of the Biosciences in Arizona. Could Arizona achieve the growth necessary to reach the top-tiers? Absolutely. Now, twenty years into the process, Arizona’s Bioindustry has a new funding catalyst. With the Governor’s vision and the Legislature’s support, an additional $1 billion dollars will be invested in university research infrastructure beginning in July of 2018. Arizona’s leaders are already discussing what the next iteration of Prop. 301 will look like as it approaches its renewal on or before 2020. The Arizona Legislature has passed HB2191 which authorizes an additional $10 million in Angel Investor Tax Credits spread over the next four years and SB1416 which continues Arizona’s Quality Jobs Tax Credit, Arizona's Research and Development Tax Credits and other business incentives. Both bills have been sent to the Governor for his signature. Arizona’s leaders are continuing the journey to take the state into the top tiers of the bioscience rankings. The Flinn Foundation has extended its commitment to steward the Arizona Bioscience Roadmap through the year 2025 with the support of the 100-person Arizona Bioscience Roadmap Steering Committee and the Arizona Bioindustry Association (AZBio) Board of Directors is committed to the vision of making Arizona a top-tier bioscience state and works collaboratively to make that vision a reality. A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners, municipalities and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world. For more information visit www.AZBio.org and www.AZBio.TV To learn more about Arizona’s Bioindustry:
News Article | May 23, 2017
SAN FRANCISCO--(BUSINESS WIRE)--The Pancreatic Cancer Action Network’s San Francisco Affiliate invites everyone to join PurpleStride San Francisco on June 18, at Justin Herman Plaza. Diane Borrison, a Bay Area resident, understands the importance of PurpleStride and its impact on the pancreatic cancer community – both locally and nationally. “As an 11-year pancreatic cancer survivor, I have a responsibility to do all I can to change the course of this devastating disease,” Borrison said. “I choose to fundraise for PurpleStride because I know that the money raised will be used to advance critical pancreatic cancer research and clinical initiatives. Through fundraising, we can create a better future for all pancreatic cancer patients.” Each year, more than 80,000 people in cities across the United States Wage Hope at PurpleStride, the walk to end pancreatic cancer. Each participant walks to improve outcomes for the nation’s deadliest cancer, one that has a five-year survival of just 9 percent. Funds raised through PurpleStride allow the Pancreatic Cancer Action Network (PanCAN) to attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Since 2003, the Pancreatic Cancer Action Network has awarded 142 grants to 143 scientists at 55 institutions, totaling $35.4 million. In addition to supporting research grants, PanCAN supports key initiatives like Precision PromiseSM, Know Your Tumor® and the Patient Registry. “Our goal at the Pancreatic Cancer Action Network is to double survival by 2020 and we are committed to making that happen,” said Julie Fleshman, JD, MBA, President and CEO of the Pancreatic Cancer Action Network. “PurpleStride is allowing us to fund key initiatives that will improve patient outcomes and ultimately help us reach our 2020 goal.” PurpleStride San Francisco will be hosted by National Emmy Award winner and CBS San Francisco anchor Joe Vazquez and will include kid-friendly activities and a purple play zone. The San Francisco event is supported by national presenting sponsor Celgene; national gold sponsor AbbVie; regional gold sponsor Cancer Treatment Centers of America, gold sponsor Halozyme, gold media sponsor KPIX5/KBCW 44 Cable 12, and silver sponsor Clovis Oncology. To register, donate or learn more about PurpleStride San Francisco, please visit purplestride.org/sanfrancisco. For more on PurpleStride and the Pancreatic Cancer Action Network, watch the PurpleStride PSA and the organization’s PSA. Follow the Pancreatic Cancer Action Network on Twitter, Instagram or on Facebook. The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double survivor by 2020.
News Article | February 22, 2017
ALEXANDRIA, Va., February 22, 2017 - CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery to improve the care of patients receiving radiation therapy. Between half and two-thirds of all cancer patients receive radiation therapy, also known as radiotherapy, to cure cancer, control its spread and relieve symptoms such as pain. At present, however, important details about radiation dose and treatment schedule are often absent from the electronic health record systems used in many oncology practices. Through the partnership, experts will develop specialized indicators for radiation-related treatment outcomes and quality that can be incorporated into the CancerLinQ platform. Inclusion of these metrics will provide a much more complete and accurate characterization of the cancer care that patients are receiving, particularly for the many situations where radiation and chemotherapy are combined. "The addition of the nation's radiation oncologists is essential to ensuring CancerLinQ's capacity to improve patient care and can help both organizations achieve outcomes that are larger and more impactful than what either one could have achieved alone," said Kevin Fitzpatrick, Chief Executive Officer of CancerLinQ LLC. "With ASTRO, we are bringing the expertise of the nation's leading physicians who specialize in treating more than one million patients each year with radiation therapy." The partnership reflects CancerLinQ's goal to create a system that encompasses all of cancer care by bringing together expertise from throughout the cancer community, as well as ASTRO's mission to improve patient outcomes through research and education. "With the number of cancer patients rising each year, collaboration across the spectrum of cancer care has to be our reality rather than our goal," said Laura Thevenot, Chief Executive Officer of ASTRO. "By combining ASTRO's domain-specific knowledge with CancerLinQ's broad reach, we can help physicians and their patients be more informed as they navigate complex treatment decisions." As an official partnering organization of CancerLinQ, ASTRO will support professional member participation in the program, advocate for streamlined data integration between leading oncology electronic health systems, and strengthen CancerLinQ's role as a go-to resource for the healthcare community. ASTRO will have access to CancerLinQ Discovery, which generates specially curated sets of de-identified clinical data from the CancerLinQ platform for oncologists, researchers and analysts to create new clinical knowledge and improve patient outcomes. In addition, ASTRO will become a founding member of the CancerLinQ Oncology Leadership Council, a body of thought leaders and oncology-affiliated experts that advises the CancerLinQ Board of Governors. CancerLinQ is a powerful database--created by oncologists for oncologists--made up of vast amounts of usable, searchable, real-world cancer information. This big data initiative will allow users to see trends among millions of patients by analyzing cancer patient medical records, uncovering patterns that can improve patient care, and enabling doctors to compare their care against that of their peers and recommended guidelines. In addition to the radiation oncologists, CancerLinQ LLC--a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO)--is forging important strategic alliances with national leaders and organizations that play important roles across the entire care continuum that support high-quality care for patients, including professionals representing the entirety of the care team, government agencies, academic research institutions, life sciences, technology experts and advocacy organizations. CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America; Chan Soon-Shiong Family Foundation; Genentech BioOncology; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD, and Susan M. DaSilva; and Susan G. Komen. CancerLinQ and CancerLinQ Discovery are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org. CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit http://www. . ASTRO is the premier radiation oncology society in the world, with more than 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics and Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, http://www. ; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www. . Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at http://www. , explore patient education resources at http://www. , and follow us on Facebook, Twitter, LinkedIn, and YouTube.
Kundranda M.N.,Banner Anderson Cancer Center |
Niu J.,Cancer Treatment Centers of America
Drug Design, Development and Therapy | Year: 2015
Albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation of paclitaxel that was initially developed more than a decade ago to overcome toxicities associated with the solvents used in the formulation of standard paclitaxel and to potentially improve efficacy. Nab-paclitaxel has demonstrated an advantage over solvent-based paclitaxel by being able to deliver a higher dose of paclitaxel to tumors and decrease the incidence of serious toxicities, including severe allergic reactions. To date, nab-paclitaxel has been indicated for the treatment of three solid tumors in the USA. It was first approved for the treatment of metastatic breast cancer in 2005, followed by locally advanced or metastatic non-small-cell lung cancer in 2012, and most recently for metastatic pancreatic cancer in 2013. Nab-paclitaxel is also under investigation for the treatment of a number of other solid tumors. This review highlights key clinical efficacy and safety outcomes of nab-paclitaxel in the solid tumors for which it is currently indicated, discusses ongoing trials that may provide new data for the expansion of nab-paclitaxel’s indications into other solid tumors, and provides a clinical perspective on the use of nab-paclitaxel in practice. © 2015 Kundranda and Niu.
News Article | February 27, 2017
BOCA RATON, Fla., Feb. 27, 2017 /PRNewswire/ -- Cancer Treatment Centers of America® (CTCA), in collaboration with NantHealth and Allscripts, is implementing a custom technical solution that, for the first time, enables eviti®, a NantHealth clinical decision support solution, access to...
News Article | February 15, 2017
Caring for Kids and Caring for Our Own Since 1967 MOUNT LAUREL, NJ--(Marketwired - February 14, 2017) - The NFL Alumni Association (NFLA) is pleased that it is celebrating 50 years of serving former players and communities around the country. Founded in 1967, the NFLA was designed to serve its retired player members and support community charities through the NFL Alumni Foundation and the "Caring for Kids" campaign. It was formed as an outgrowth of philanthropic and civic-minded impulses of retired NFL players who performed at the highest level of the nation's most popular sport. The NFLA now is comprised of former NFL players, coaches, staffers, cheerleaders, spouses, and associate members. "Being the President and CEO of the NFL Alumni Association the past four years has been an honor and a privilege," says former Giants & Eagles quarterback Joe Pisarcik. "The growth that our organization has seen is incredible. Our Board of Directors, Chapter Presidents, and NFLA staff concentrate on providing former players and their families the best benefits possible. We also serve as 'information central' to help make sure they are aware of the all programs available to retired NFL players. As we celebrate our Golden Anniversary, I'm looking forward to the future and take pride in being the most well-known and well-respected NFL retired player organization." The primary focus of the NFLA is to serve, assist, and inform players in their post-NFL lives. The Association is constantly introducing and offering programs from a variety of medical, financial, educational, and social plans to help keep members and their families healthy, productive, and connected. Some of the medical services offered are Teladoc, Cancer Treatment Centers of America, Premier Stem Cell Treatments, and LabCorp. "I am very proud to be Chairman of the Board for the NFL Alumni," says former NFL quarterback and ESPN NFL analyst Ron Jaworski. "There are an estimated 22,000 retired NFL football players, and we at the NFL Alumni strive to provide impactful benefits that will assist them in their transition from the game and in their post-NFL lives off the field." The NFLA also continues to support organizations and projects which offer special promise of advancing the quality of life in communities where Alumni chapters are located. Each chapter works to expand its outreach in the community through year-round participation by Alumni members in fundraising and personal-service programs to assist other charitable organizations. Alumni members are currently part of 34 local chapters where they can connect with other former players to raise money for children's charities. Together, the NFLA raises more than $1 million a year for local nonprofit causes. The NFL Alumni Association in 2013 also developed an iconic, additional logo and name -- Pro Football Legends (PFL) -- which is the marketing brand used for its commercial activities. PFL is used by the NFLA to increase strategic business relationships in order to create additional opportunities for its NFL Alumni members. NFLA's mission of "Caring for Kids and Caring for Our Own" is more than just a statement. It is a strong commitment to making a positive impact on the communities that host our chapters nationwide. Our members have done so for five decades and look forward to many more years of serving our communities and assisting our retired players and their families. About the NFL Alumni Association The NFL Alumni Association is a nationwide group of former NFL players, coaches, staffers, cheerleaders, spouses, and associate members whose mission is to serve, assist, and inform former players and their families. The Association offers a variety of medical, financial, and social programs to help members lead healthy, productive, and connected lives, as well as community initiatives under its "Caring for Kids" programs. Pro Football Legends is the commercial marketing name and logo of the NFL Alumni. For more information, please visit www.nflalumni.org.
Markman M.,Cancer Treatment Centers of America
JNCCN Journal of the National Comprehensive Cancer Network | Year: 2011
Unfortunately, no reliable evidence-based data have shown any in vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use. Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches. © JNCCN-Journal of the National Comprehensive Cancer Network.
Markman M.,Cancer Treatment Centers of America
Gynecologic Oncology | Year: 2013
There has been limited change in evidence-based primary chemotherapeutic management of optimal residual advanced ovarian cancer for more than a decade. The backbone of therapy remains a platinum agent (generally carboplatin) and a taxane (generally paclitaxel). Phase 3 randomized trial data provide support for the use of weekly paclitaxel in this setting (compared to the traditional every 3-week schedule) and the addition of bevacizumab as a component of primary management. Recently available data provide increasingly solid support for a role of regional platinum administration in at least a subset of patients with optimal residual advanced ovarian cancer and an important retrospective analysis has suggested a novel biomarker that may predict for the utility (or lack thereof) of this method of drug delivery. © 2013 Elsevier Inc. All rights reserved.